News

NGR-hTNF is a vascular targeting agent belonging to peptide/cytokine complexes, which can selectively target the tumour vasculature. The randomised, double-blind, placebo-controlled, multicentre Phase III NGR015 trial, will enroll

The double-blind, randomized, placebo-controlled dose-ranging study, assessed the pharmacokinetics, safety and tolerability of BAL30072 in healthy volunteers following multiple ascending doses of intravenous infusions. The trial demonstrated that

AB103 is a short peptide acting as a CD28 modulator which regulates the inflammatory response in the host. The drug candidate is said to have completed a phase

ProBioGen’s GlymaxX ADCC enhancement technology, mammalian cell line development and manufacturing services will be employed to advance therapeutic antibodies developed by Inhibrx. Under the terms of the collaboration,

AP301, an orally inhaled drug candidate is used against respiratory failure caused by pulmonary oedema that activates lung oedema reabsorption. The Phase I single-center clinical trial assessed the

HuMax-TF is a fully human antibody targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. As per the deal, Genmab gets development and cGMP

Two-thirds of the enrolled patients were less than four years old. Shigamabs consists of two monoclonal antibodies which bind to the Shiga toxin 1 and Shiga toxin 2

As part of the acquisition, Biostar has changed its name to Shaanxi Weinan Aoxing Pharmaceuticals. Next to the acquisition, Biostar has increased its portfolio of drug approvals and

Rivastigmine Capsules are the generic forms of Novartis’ Exelon Capsules. Mylan chairman and CEO Robert Coury said they are excited to be adding generic Rivastigmine to their portfolio